Vaped Phenanthrene for Ex-Smokers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how former smokers’ lungs process phenanthrene, a chemical linked to cancer risk. By determining if former smokers break down this chemical more harmfully than those who never smoked, researchers aim to find better ways to prevent or treat lung cancer. Participants will vape a version of phenanthrene (D10-phenanthrene) to assess how their lungs handle cancer-causing substances. The trial suits former daily cigarette smokers who quit 1 to 20 years ago, have tried vaping, and are in good physical and mental health. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to new preventive strategies for lung cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that vaping D10-phenanthrene is safe for former smokers and non-smokers?
Research shows that D10-phenanthrene can irritate the skin or eyes upon contact and may irritate the lungs if inhaled. However, using it in small, controlled amounts, as in this study, has not been associated with any serious effects. Safety sheets indicate that it can expose individuals to chemicals that might cause cancer according to California regulations. While this may sound concerning, it's important to note that in this study, D10-phenanthrene is used to understand how certain chemicals break down in the lungs, not as a treatment. For any safety concerns, consult the study team or a healthcare provider.12345
Why are researchers excited about this trial?
Unlike traditional treatments for managing exposure to cancer-causing chemicals, which often involve quitting smoking or using medications to help detoxify the body, D10-phenanthrene offers a unique approach. Researchers are excited about D10-phenanthrene because it allows them to study how the lungs of former smokers and non-smokers break down harmful polycyclic aromatic hydrocarbons (PAHs) when inhaled through vaping. This could provide new insights into the body's ability to process these dangerous compounds, potentially leading to innovative strategies for reducing cancer risk in ex-smokers.
What evidence suggests that this method is effective for studying lung cancer risk in ex-smokers?
Research has shown that certain chemicals in cigarette smoke, known as polycyclic aromatic hydrocarbons (PAHs), likely cause lung cancer. The body must activate these chemicals for them to become harmful. Studies have found that smoking increases the activation of these harmful chemicals in the lungs. Even after quitting, former smokers might still process these chemicals in harmful ways. In this trial, participants will vape D10-phenanthrene to track how the body processes these chemicals. This understanding could lead to better prevention or treatment of lung cancer in former smokers.678910
Who Is on the Research Team?
Stephen Hecht
Principal Investigator
University of Minnesota
Are You a Good Fit for This Trial?
This trial is for former smokers who have quit smoking but may still be at risk of lung cancer. It aims to understand how their lungs process certain chemicals compared to those who never smoked. Participants must meet specific criteria not detailed here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Vaping Phenanthrene
Participants vape D10-phenanthrene to study lung breakdown of PAHs
Follow-up
Participants are monitored for safety and effectiveness after vaping
What Are the Treatments Tested in This Trial?
Interventions
- D10-phenanthrene
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor